What happens to regulatory T cells in multiple myeloma

被引:0
|
作者
Chen, Huixian [1 ,2 ]
Wang, Xueling [1 ,3 ]
Wang, Yan [4 ]
Chang, Xiaotian [1 ]
机构
[1] Qingdao Univ, Affiliated Hosp, Med Res Ctr, Qingdao 266003, Peoples R China
[2] Qingdao Univ, Affiliated Hosp, Dept Hematol, Qingdao 266003, Peoples R China
[3] Qingdao Univ, Affiliated Hosp, Dept Gastroenterol, Qingdao 266003, Peoples R China
[4] Shandong Univ, Qilu Hosp, Dept Pediat, Jinan 250012, Peoples R China
关键词
TRANSCRIPTION FACTOR FOXP3; NATURAL-KILLER-CELL; PERIPHERAL-BLOOD; BONE-MARROW; SUPPRESSOR-CELLS; CD127; EXPRESSION; DENDRITIC CELLS; FUNCTIONAL-CHARACTERIZATION; INTERLEUKIN (IL)-2; ANTITUMOR IMMUNITY;
D O I
10.1038/s41420-023-01765-8
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Abnormal tumor microenvironment and immune escape in multiple myeloma (MM) are associated with regulatory T cells (Tregs), which play an important role in maintaining self-tolerance and regulating the overall immune response to infection or tumor cells. In patients with MM, there are abnormalities in the number, function and distribution of Tregs, and these abnormalities may be related to the disease stage, risk grade and prognosis of patients. During the treatment, Tregs have different responses to various treatment regiments, thus affecting the therapeutic effect of MM. It is also possible to predict the therapeutic response by observing the changes of Tregs. In addition to the above, we reviewed the application of Tregs in the treatment of MM. In conclusion, there is still much room for research on the mechanism and application of Tregs in MM.
引用
收藏
页数:12
相关论文
共 50 条
  • [1] Regulatory T-Cells and Multiple Myeloma: Implications in Tumor Immune Biology and Treatment
    Hadjiaggelidou, Christina
    Katodritou, Eirini
    JOURNAL OF CLINICAL MEDICINE, 2021, 10 (19)
  • [2] Increased T Regulatory Cells Are Associated with Adverse Clinical Features and Predict Progression in Multiple Myeloma
    Raja, Karthick Raja Muthu
    Rihova, Lucie
    Zahradova, Lenka
    Klincova, Maria
    Penka, Miroslav
    Hajek, Roman
    PLOS ONE, 2012, 7 (10):
  • [3] The frequency of T regulatory cells modulates the survival of multiple myeloma patients: detailed characterisation of immune status in multiple myeloma
    Giannopoulos, K.
    Kaminska, W.
    Hus, I.
    Dmoszynska, A.
    BRITISH JOURNAL OF CANCER, 2012, 106 (03) : 546 - 552
  • [4] The Role of Regulatory T Cells and TH17 Cells in Multiple Myeloma
    Braga, Walter M. T.
    Atanackovic, Djordje
    Colleoni, Gisele W. B.
    CLINICAL & DEVELOPMENTAL IMMUNOLOGY, 2012,
  • [5] What are regulatory T cells (Treg) regulating in cancer and why?
    Whiteside, Theresa L.
    SEMINARS IN CANCER BIOLOGY, 2012, 22 (04) : 327 - 334
  • [6] Myeloma cells act as tolerogenic antigen-presenting cells and induce regulatory T cells in vitro
    Frassanito, Maria Antonia
    Ruggieri, Simona
    Desantis, Vanessa
    Di Marzo, Lucia
    Leone, Patrizia
    Racanelli, Vito
    Fumarulo, Ruggiero
    Dammacco, Franco
    Vacca, Angelo
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2015, 95 (01) : 65 - 74
  • [7] Contribution of regulatory T cells to immunosuppression and disease progression in multiple myeloma patients
    Raja, Karthick Raja Muthu
    Hajek, Roman
    ONCOIMMUNOLOGY, 2013, 2 (09)
  • [8] The frequency of T regulatory cells modulates the survival of multiple myeloma patients: detailed characterisation of immune status in multiple myeloma
    K Giannopoulos
    W Kaminska
    I Hus
    A Dmoszynska
    British Journal of Cancer, 2012, 106 : 546 - 552
  • [9] Targeting regulatory T cells in tumors
    Liu, Chang
    Workman, Creg J.
    Vignali, Dario A. A.
    FEBS JOURNAL, 2016, 283 (14) : 2731 - 2748
  • [10] Regulatory T cells in gastrointestinal tumors
    Raghavan, Sukanya
    Quiding-Jarbrink, Marianne
    EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY, 2011, 5 (04) : 489 - 501